Tags : P-IV

BMS Reports Results of Orencia (abatacept) in P-IV Early AMPLE

Shots: The P-IV Early AMPLE mechanistic study results involve assessing of Orencia (125 mg, SC) vs adalimumab (40mg, SC) on a background of MTX in 80 patients in a ratio (1:1) with moderate-to-severe RA seropositive for anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF) The P-IV Early AMPLE study results: @24wks. ACR 20/50/70 responses (83/70/48 […]Read More

Astellas Reports Results of Mirabegron in P-IV PLUS Study to

Shots: The P-IV PLUS study involves assessing of Mirabegron(25mg,50mg) vs PBO in 715 men patients with overactive bladder (OAB) symptoms receiving tamsulosin for lower urinary tract symptoms (LUTS) due to underlying benign prostatic hyperplasia (BPH) aged ≥40 yrs. The P-IV PLUS study results: @12wks. reduction in no. of micturition/day, increment in mean volume voided (MVV)/micturition, […]Read More